Funded Biotechnology Startups in Lausanne
The 21 rounds shown span from May 2020 to October 2025, with notable concentration of activity in 2024 and 2025.
The 21 rounds shown span from May 2020 to October 2025, with notable concentration of activity in 2024 and 2025. Lausanne's biotechnology deal flow covers a wide check-size range — MindMaze raised $105M in a venture round in February 2022, while SensArs closed a $30K Seed in September 2024 and multiple companies recorded sub-$200K financings. Two $65M Series A rounds, HAYA Therapeutics (May 8) and ReproNovo (May 21, 2025), closed within two weeks of each other, an unusual pairing of identically sized growth rounds.
Several rounds carry "Series Unknown" labels despite meaningful disclosed amounts: ADC Therapeutics ($60M, February 2023) and AC Immune ($50M, December 2023) are the clearest examples. GenKnowme and Roumai Medical both filed rounds on February 9, 2024, each with undisclosed amounts. The dataset includes two Series D-stage companies — Timeline ($65M, January 2024) and Lunaphore ($33M, March 2023) — alongside pre-seed, convertible note, and debt financing structures.
Most recent rounds
21 shownRelated listings
Frequently asked
What are the largest rounds in this Lausanne biotech listing?
MindMaze leads with a $105M venture round from February 2022. Three companies — Timeline, ReproNovo, and HAYA Therapeutics — each raised $65M, with Timeline's at Series D (January 2024) and the other two as Series A rounds in May 2025. ADC Therapeutics ($60M, February 2023) and AC Immune ($50M, December 2023) round out the top tier, though both carry Series Unknown labels.
How active has Lausanne biotech funding been in 2025?
Four rounds appear in 2025 within this dataset: HAYA Therapeutics and ReproNovo each closed $65M Series A rounds in the first three weeks of May, SamanTree Medical raised $6M at Series B in April, and Hemostod closed a $5M Seed in October. The two May closes, separated by 13 days, represent $130M of 2025's disclosed activity.
How wide is the deal-size range across these companies?
The spread runs from $30K (SensArs, Seed, September 2024) to $105M (MindMaze, February 2022). Several rounds fall below $200K — including Abionic ($80K), Adaptyv Biosystems ($110K), and Calico Biosystems ($170K) — placing institutional venture rounds and sub-angel financings in the same dataset.
Which companies here have reached later funding stages?
Timeline (Series D, $65M, January 2024) and Lunaphore (Series D, $33M, March 2023) are the most advanced by labeled round stage. MindMaze's $105M raise in February 2022 is categorized as Venture - Series Unknown, suggesting a mature company whose precise stage was not publicly disclosed.
How complete is the round-type and amount data in this listing?
Two companies — GenKnowme and Roumai Medical — list undisclosed amounts for rounds filed on the same date (February 9, 2024), and two others, Alithea Genomics and Emovo Care, carry no round-type label at all. Several sizeable raises, including ADC Therapeutics at $60M and AC Immune at $50M, are classified as Series Unknown rather than a specific lettered round.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.